UK-specific guidance for the application and management of clinical trials in the context of COVID-19
The UK’s MHRA has stated it will be particularly flexible and pragmatic in authorising clinical trials connected to COVID-19, referring to its previous track record of having acted swiftly in past public health crises
As noted in our previous overview article, it is vital that interested companies continue to monitor and strategically act on the rapidly changing government position on the regulation of specific medical supply product types in the context of COVID-19.
We all hope that the predictions about the spread and seriousness of COVID-19 (coronavirus) prove to be unfounded. Whatever course the development of the virus takes, many of the measures that have been taken or are under consideration by governments, businesses and other organisations are already having or will have a significant effect on commercial relationships and commercial life generally.
This is not a class action: proposed directive to introduce group actions across the EU gaining momentum
Jamie Humphreys and Tracey Bischofberger
The EU has been pushing ahead with proposed new legislation to introduce representative actions across the EU. The proposed new EU-wide rules will apply to infringements of a broad range of EU laws that harm the collective interests of consumers including in the areas of consumer rights, data protection, product liability and product safety.